Key takeaways
Kesimpta (ofatumumab) and Vumerity (diroximel fumarate) are both medications used to treat relapsing forms of multiple sclerosis (MS). However, they belong to different medication classes. Kesimpta is a monoclonal antibody that is injected under the skin, while Vumerity is a fumaric acid derivative taken orally as a capsule. Kesimpta is typically injected once a month after an initial three-week period of weekly injections, whereas Vumerity is taken twice daily. Kesimpta and Vumerity are available only as a brand-name medications. Common side effects of Kesimpta include injection site reactions and headaches, while Vumerity often causes flushing and stomach pain. Both medications can increase the risk of infections, but Kesimpta also requires caution with live vaccines, and Vumerity may affect liver function and white blood cell counts.
